Robinson Value Management Ltd. Invests $2.39 Million in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Robinson Value Management Ltd. acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,787 shares of the company’s stock, valued at approximately $2,393,000. IDEXX Laboratories comprises about 1.6% of Robinson Value Management Ltd.’s investment portfolio, making the stock its 25th biggest position.

Several other hedge funds have also made changes to their positions in the business. Angeles Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 2.4% during the third quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company’s stock worth $545,000 after purchasing an additional 25 shares during the last quarter. Cranbrook Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 7.0% during the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company’s stock worth $158,000 after purchasing an additional 25 shares during the last quarter. Perigon Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 1.8% during the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company’s stock worth $632,000 after purchasing an additional 26 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of IDEXX Laboratories by 4.0% during the third quarter. First Horizon Advisors Inc. now owns 704 shares of the company’s stock worth $356,000 after purchasing an additional 27 shares during the last quarter. Finally, Concurrent Investment Advisors LLC raised its position in shares of IDEXX Laboratories by 4.7% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 630 shares of the company’s stock worth $318,000 after buying an additional 28 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.2 %

Shares of NASDAQ IDXX opened at $459.78 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The firm has a market cap of $37.65 billion, a price-to-earnings ratio of 43.09, a PEG ratio of 3.47 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31. The stock’s 50-day simple moving average is $428.35 and its 200-day simple moving average is $453.56.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IDXX. Leerink Partners began coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Piper Sandler reissued a “neutral” rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $524.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.